Small Business Innovation Research · Small Business Technology Transfer
Mapp Biopharmaceutical, Inc.: SBIR & STTR awards
26 awards worth $26.01M to 1 companies since 2004 match these filters. Phase I tests an idea (usually a few hundred thousand dollars); Phase II builds it (often $1M or more).
Mapp Biopharmaceutical, Inc.'s federal contracts and grants · All SBIR & STTR awards
Awards by year
| Year | Phase I | Phase II | Amount |
|---|---|---|---|
| 2025 | 1 | 1 | $1.29M |
| 2020 | 0 | 1 | $2.75M |
| 2018 | 2 | 0 | $898.0K |
| 2017 | 2 | 1 | $3.48M |
| 2016 | 1 | 0 | $240.2K |
| 2015 | 1 | 0 | $228.8K |
| 2014 | 2 | 2 | $6.13M |
| 2012 | 1 | 0 | $300.0K |
| 2011 | 0 | 1 | $3.00M |
| 2010 | 1 | 0 | $600.0K |
| 2009 | 1 | 0 | $524.9K |
| 2008 | 1 | 1 | $3.42M |
The latest year fills in over months: agencies report awards to SBIR.gov with a lag.
Latest matching awards
| Award | Company | Agency | Phase | Amount | Date |
|---|---|---|---|---|---|
| Development of highly potent human monoclonal for RSV immunoprophylaxis · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $993.4K | 2025-09-24 |
| A Novel Cost-Effective Multispecific Therapeutic for Dengue · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $294.6K | 2025-06-09 |
| Development of highly potent human monoclonal for RSV immuno-prophylaxis · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.75M | 2020-07-02 |
| Post-exposure immunotherapy for ricin exposure · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $298.0K | 2018-06-29 |
| Development of highly potent human monoclonals for RSV immunoprophylaxis · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $600.0K | 2018-01-15 |
| Direct Sequencing of Antibodies of the Influenza Immune Response · topic NCIRD | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · Centers for Disease Control and Prevention | SBIR Phase I | $225.0K | 2017-09-01 |
| MR191_An Immunoprotectantfor Marburg Virus · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $3.00M | 2017-07-01 |
| Direct sequencing of serum antibodies after infection · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $255.0K | 2017-02-01 |
| Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $240.2K | 2016-08-01 |
| Pseudomonas antibodies with designed glycans · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $228.8K | 2015-01-05 |
| An SEB Immunoprotectant · topic R | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.31M | 2014-08-20 |
| An Immunoprotectant for Marburg Virus · topic R | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $3.00M | 2014-07-01 |
| A human monoclonal for RSV prophylaxis · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $600.0K | 2014-07-01 |
| Novel Immunotherapy for Brain Cancer · topic NCI | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $225.0K | 2014 |
| A Monoclonal Cocktail for CDI · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $300.0K | 2012 |
| A Monoclonal Antibody Immunoprotectant for Ebola Virus · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $3.00M | 2011 |
| Development of a monoclonal immunoprotectant for ricin · topic NIAID | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $600.0K | 2010 |
| An Immunoprotectant for Marburg Virus | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $524.9K | 2009 |
| Monoclonal Antibodies for Alzheimer's Immunotherapy | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.82M | 2008 |
| Monoclonal Antibody SEB Immunoprotectant | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $599.8K | 2008 |
| Development of a C. difficile Monoclonal-based Product | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $997.0K | 2007 |
| A Monoclonal Antibody Immunoprotectant for Ebola Virus | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $270.8K | 2007 |
| A HUMAN MONOCLONAL COCKTAIL FOR RSV IMMUNOTHERAPY | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $571.0K | 2006 |
| A HUMAN MONOCLONAL COCKTAIL FOR RSV IMMUNOTHERAPY | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $571.0K | 2006 |
| MONOCLONAL ANTIBODIES FOR ALZHEIMER'S IMMUNOTHERAPY | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $445.9K | 2005 |
| ANTI-C. DIFFICILE HUMAN MONOCLONALS FOR IMMUNOTHERAPY | Mapp Biopharmaceutical, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $300.0K | 2004 |
Source: SBIR.gov award data (SBA) ↗, awards through 2026-08-28. Amounts are as agencies report them to SBA. SBIR/STTR contracts also appear in USAspending as ordinary awards; grants (NIH, NSF, DOE) appear as assistance. Open topics are posted by each agency; see Opportunities for contract notices.